Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMP | P19971 | 5/20 | 0.46 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.40 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.40 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.39 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.38 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23023835 | 0.90 | TYMP (0.39) | TYMPADORA1 | |
| SCHEMBL28628224 | 0.88 | TYMP (0.48) | TYMPADORA2AADORA2BADORA1PRMT6 | |
| SCHEMBL28426419 | 0.88 | TYMP (0.48) | TYMPADORA2AADORA2BADORA1PRMT6 | |
| SCHEMBL18797945 | 0.88 | TYMP (0.48) | TYMPADORA2AADORA2BADORA1PRMT6 | |
| SCHEMBL18797938 | 0.88 | TYMP (0.46) | TYMPADORA2AADORA2BADORA1PRMT6 | |
| SCHEMBL20591788 | 0.88 | TYMP (0.46) | TYMPADORA2AADORA2BADORA1PRMT6 | |
| SCHEMBL8380846 | 0.87 | TYMP (0.51) | TYMPADORA2AADORA2BADORA1PRMT6 | |
| SCHEMBL20337102 | 0.87 | TYMP (0.41) | TYMPADORA2AADORA2BADORA1PRMT6 | |
| SCHEMBL21591934 | 0.86 | TYMP (0.55) | TYMPADORA2AADORA2BADORA1P2RY12 | |
| SCHEMBL21305068 | 0.86 | TYMP (0.55) | TYMPADORA2AADORA2BADORA1PRMT6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12036231-B2 | Cyclic dinucleotides as agonists of stimulator of interferon gene dependent signalling | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-07-16 | — | — | US | disclosed |
| EP-3873484-B1 | NOVEL STING AGONISTS | VENENUM BIODESIGN LLC (US) | 2023-08-23 | — | — | EP | disclosed |
| US-20220347201-A1 | CYCLIC DINUCLEOTIDES AS AGONISTS OF STIMULATOR OF INTERFERON GENE DEPENDENT SIGNALLING | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2022-11-03 | — | — | US | disclosed |
| US-20220048936-A1 | NOVEL STING AGONISTS | Venenum Biodesign, LLC (US) | 2022-02-17 | — | — | US | disclosed |
| US-11161864-B2 | Sting agonists | Venenum Biodesign, LLC (US) | 2021-11-02 | — | — | US | disclosed |
| CN-107849084-B | Cyclic purine dinucleotides as STING modulators | 葛兰素史密斯克莱知识产权发展有限公司 | 2021-09-14 | — | — | CN | disclosed |
| US-20210236531-A1 | CYCLIC DINUCLEOTIDES AS AGONISTS OF STIMULATOR OF INTERFERON GENE DEPENDENT SIGNALLING | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2021-08-05 | — | — | US | disclosed |
| US-10975114-B2 | Bis 2′-5′-RR-(3′F-A)(3′F-A) cyclic dinucleotide compound and uses thereof | CHINOOK THERAPEUTICS, INC. (US) | 2021-04-13 | — | — | US | disclosed |
| US-10933078-B2 | Cyclic dinucleotides as agonists of stimulator of interferon gene dependent signalling | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2021-03-02 | — | — | US | disclosed |
| US-10906930-B2 | Compositions and methods for activating “stimulator of interferon gene”-dependent signalling | CHINOOK THERAPEUTICS, INC. (US) | 2021-02-02 | — | — | US | disclosed |
| EP-3366691-A1 | CYCLIC PURINE DINUCLEOTIDES AS MODULATORS OF STING | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2018-08-29 | — | — | EP | disclosed |
| US-9994607-B2 | Compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-06-12 | — | — | US | disclosed |
| EP-3322713-A1 | CYCLIC PURINE DINUCLEOTIDES AS MODULATORS OF STING | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2018-05-23 | — | — | EP | disclosed |
| WO-2018009466-A1 | LOCKED NUCLEIC ACID CYCLIC DINUCLEOTIDE COMPOUNDS AND USES THEREOF | Aduro Biotech, Inc. (US) | 2018-01-11 | — | — | WO | disclosed |
| US-20170233430-A1 | Novel Compounds | GLAXOSMITHKLINE LLC | 2017-08-17 | — | — | US | disclosed |
| US-9718848-B2 | Compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-08-01 | — | — | US | disclosed |
| WO-2017106740-A1 | METHODS FOR IDENTIFYING INHIBITORS OF \"STIMULATOR OF INTERFERON GENE\"-DEPENDENT INTERFERON PRODUCTION | Aduro Biotech, Inc. (US) | 2017-06-22 | — | — | WO | disclosed |
| US-20170158724-A1 | Novel Compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-06-08 | — | — | US | disclosed |
| WO-2017093933-A1 | CYCLIC PURINE DINUCLEOTIDES AS MODULATORS OF STING | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-06-08 | — | — | WO | disclosed |
| WO-2017075477-A1 | COMPOSITIONS AND METHODS FOR ACTIVATING \"STIMULATOR OF INTERFERON GENE\"-DEPENDENT SIGNALLING | Aduro Biotech, Inc. (US) | 2017-05-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170233430-A1 | Novel Compounds | STING1, IRF3, IFNAR1 | TYMP 1531/4885ADORA2A 766/4885ADORA2B 386/4885 |
| US-11161864-B2 | Sting agonists | STING1, IRF3, CGAS | TYMP 3035/4885ADORA2A 342/4885ADORA2B 461/4885 |
| US-12036231-B2 | Cyclic dinucleotides as agonists of stimulator of interferon gene dependent signalling | STING1, IRF3, CGAS | TYMP 284/4885ADORA2A 304/4885ADORA2B 636/4885 |
| US-10906930-B2 | Compositions and methods for activating “stimulator of interferon gene”-dependent signalling | STING1, IRF3, CGAS | TYMP 2232/4885ADORA2A 193/4885ADORA2B 585/4885 |
| US-20220347201-A1 | CYCLIC DINUCLEOTIDES AS AGONISTS OF STIMULATOR OF INTERFERON GENE DEPENDENT SIGNALLING | STING1, IRF3, CGAS | TYMP 284/4885ADORA2A 304/4885ADORA2B 636/4885 |
| US-20170158724-A1 | Novel Compounds | STING1, IRF3, IFNAR1 | TYMP 1531/4885ADORA2A 766/4885ADORA2B 386/4885 |
| US-20210236531-A1 | CYCLIC DINUCLEOTIDES AS AGONISTS OF STIMULATOR OF INTERFERON GENE DEPENDENT SIGNALLING | STING1, IRF3, CGAS | TYMP 284/4885ADORA2A 304/4885ADORA2B 636/4885 |
| US-20220048936-A1 | NOVEL STING AGONISTS | STING1, IRF3, CGAS | TYMP 2997/4885ADORA2A 267/4885ADORA2B 401/4885 |
| US-10975114-B2 | Bis 2′-5′-RR-(3′F-A)(3′F-A) cyclic dinucleotide compound and uses thereof | STING1, IRF3, IFNAR1 | TYMP 1907/4885ADORA2A 86/4885ADORA2B 238/4885 |
| US-10933078-B2 | Cyclic dinucleotides as agonists of stimulator of interferon gene dependent signalling | STING1, IRF3, CGAS | TYMP 284/4885ADORA2A 304/4885ADORA2B 636/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.